KR102136384B1 - Nanofibers containing two kinds of reagents for the diagnosis of urinary tract infection, nanofiber membranes containing the nanofibers, and a method for producing the same - Google Patents

Abstract

The nanofibers comprise irregularly arranged nanofibers, the nanofibers comprise a composite nanofiber comprising a first reagent and a second reagent, the first reagent produces a hydrolysis compound by leukocyte esterase, and the second reagent Disclosed is a nanofibrous membrane for diagnosing urinary tract infection that displays a color indicating the presence of leukocyte esterase by reacting with the hydrolyzed compound.

Description

Nanofibers containing two kinds of reagents for the diagnosis of urinary tract infection, nanofiber membranes containing the nanofibers, and a method for producing the same }

The present invention relates to nanofibers containing reagents for diagnosing two types of urinary tract infections, nanofiber membranes comprising the same, and methods for manufacturing the same.

Urinary tract infection is a common bacterial disease in childhood, which means a bacterial infection in the urethra, bladder and kidneys. Urinary tract infections are accompanied by fever and pain. However, it is difficult for infants or the elderly, who have difficulty communicating, to notify the caregiver of symptoms of urinary tract infection. In addition, the symptoms of urinary tract infection are similar to those of the cold, so it is difficult for the guardian to know the patient's urinary tract infection. For this reason, infants or the elderly often visit the hospital after urinary tract infection has progressed significantly. Therefore, in order to prevent this, there is an inconvenience in that the guardian must continuously observe the victim and be diagnosed by visiting the hospital frequently.

In general, urinary tract infection is diagnosed by urine test and urine culture test. Of these, urine testing is one of the simplest and fastest ways to diagnose urinary tract infections. In the diagnosis of urinary tract infection by urine test, a diagnostic kit that can be easily visually examined by changing the color in response to leukocyte esterase in urine is generally used.

However, urine testing requires a sample of the patient's urine. Infants, the elderly, and patients with mobility disabilities have difficulty in providing urine samples on their own, so there is a discomfort that requires the help of a guardian. There is also the inconvenience of visiting the hospital and providing samples. Therefore, a quick and simple urinary tract infection diagnosis means is required to solve the above problems.

Electrospinning is a means to produce fibers and fiber membranes in the nanometer range. Electrospinning has the advantage that it can be made of fibers using materials that were difficult to produce with fibers using conventional fiber manufacturing methods, and can also be made into non-woven fabrics.

Electrospinning can produce nanometer-diameter fibers by releasing a polymer solution through a spinneret (or may also be referred to as a nozzle) over a high voltage. When a high voltage electric field is applied to the polymer solution of the spinneret, the positively charged polymer solution is discharged from the spinneret and collects in the negatively charged current collector. The polymer solution of the spinneret is in equilibrium between gravity and surface tension and forms hemispherical droplets. When an electric field is applied, electric charges are induced on the surface of the hemispherical droplets, and repulsion of electric charges creates a force opposite to the surface tension (Taylor cone formation). When a specific voltage is applied, one jet is formed from the polymer solution, and the evaporation of the solvent may split into several fibers having a nanometer diameter. The split fibers may be irregularly collected in the negatively charged current collector to form a nonwoven fabric.

Electrospinning is said to be easy to produce functional fibers. As a method of manufacturing a functional fiber, a method of manufacturing a polymer solution containing a functional material by spinning is known. It is known that fabrication of functional fibers by electrospinning can produce thin diameter fibers and contain fewer reagents. However, the polymer solution containing the functional material has a problem that cutting occurs during spinning if the conditions are not appropriate.

Korean Registered Patent Publication No. 10-2011-0018114 (2011.02.23)

According to an embodiment of the present invention, there is provided a method of manufacturing a nanofibrous membrane for urinary tract infection diagnosis capable of diagnosing urinary tract infection.

According to an embodiment of the present invention provides a method for manufacturing a nanofibrous membrane for urinary tract infection diagnosis that does not occur when electrospinning.

According to an embodiment of the present invention, there is provided a method of manufacturing a nanofibrous membrane for diagnosing urinary tract infection that contains less reagent for diagnosing urinary tract infection.

According to an embodiment of the present invention provides a nanofibrous membrane for urinary tract infection diagnosis that can diagnose urinary tract infection.

According to an exemplary embodiment of the present invention, a nanofiber membrane for diagnosing a urinary tract infection having a thin thickness is provided.

According to an exemplary embodiment of the present invention, a nanofibrous membrane for diagnosing urinary tract infection containing less reagent for diagnosing urinary tract infection is provided.

The nanofibrous membrane for urinary tract infection diagnosis according to an embodiment of the present invention includes irregularly arranged nanofibers, the nanofibers include a composite nanofiber including a first reagent and a second reagent, and the first reagent is a white blood cell A hydrolyzed compound is produced by esterase, and the second reagent reacts with the hydrolyzed compound to exhibit a color indicating the presence of leukocyte esterase.

The nano-fiber membrane for diagnosing urinary tract infection according to an embodiment of the present invention further includes a diffusion barrier layer laminated on the nanofiber membrane for diagnosing urinary tract infection.

The apparatus for diagnosing urinary tract infection according to an embodiment of the present invention includes the nanofibrous membrane for diagnosing urinary tract infection.

In the method of manufacturing a nanofibrous membrane for urinary tract infection diagnosis according to an embodiment of the present invention, a first reagent for generating a hydrolyzed compound by reacting with a leukocyte esterase and a color indicating the presence of a leukocyte esterase by reacting with the hydrolyzed compound And preparing a composite polymer solution containing the second reagent shown and electrospinning the composite polymer solution into a current collector.

The method of manufacturing a nanofibrous membrane for diagnosing urinary tract infection according to an embodiment of the present invention may contain a reagent for diagnosing urinary tract infection when electrospinning, but may not cause truncation.

The nanofibrous membrane for diagnosing urinary tract infection according to an embodiment of the present invention can visually confirm urinary tract infection.

The nanofibrous membrane for diagnosing urinary tract infection according to an embodiment of the present invention may contain less reagent for diagnosing urinary tract infection.

The nanofibrous membrane for diagnosing urinary tract infection according to an embodiment of the present invention may have a thin thickness and minimize the increase in volume when attached to a hygiene product.

The nanofibrous membrane for diagnosing urinary tract infection according to an embodiment of the present invention may improve the accuracy of urinary tract infection confirmation.

The nanofibrous membrane for diagnosing urinary tract infection according to an embodiment of the present invention may be flexible, and may be easily applied to sanitary products whose shape needs to be modified according to movement.

1 shows an SEM photograph of a nanofiber membrane according to an embodiment of the present invention.
2 is a first reagent according to an embodiment of the present invention, for the description of the nano-fiber structure is a representation of the first reagent 10 in a spherical shape.
3 is in the second reagent according to an embodiment of the present invention, for the description of the nano-fiber structure, the second reagent 20 is represented by a cube.
4 illustrates a composite nanofiber 100 including a first reagent 10 and a second reagent 20 according to an embodiment of the present invention.
5 shows a partial structure of the nanofiber membrane in which the composite nanofiber 100 according to an embodiment of the present invention is irregularly arranged.

The nanofibrous membrane for urinary tract infection diagnosis according to an embodiment of the present invention includes irregularly arranged nanofibers, the nanofibers include a composite nanofiber including a first reagent and a second reagent, and the first reagent is a white blood cell A hydrolyzed compound is produced by esterase, and the second reagent reacts with the hydrolyzed compound to exhibit a color indicating the presence of leukocyte esterase.

The urinary tract infection diagnosis nanofiber membrane may be a porous structure in which nanofibers are irregularly arranged and accumulated, for example, a structure similar to a nonwoven fabric.

The composite nanofiber means a nanofiber including both the first reagent and the second reagent.

Referring to FIG. 1, the nanofibrous membrane for diagnosing urinary tract infection forms a porous structure such as a nonwoven fabric by arranging the composite nanofibers irregularly. Since the nano-fiber membrane has a thin thickness, it may be advantageous for the reduction or miniaturization of a urinary tract infection diagnosis instrument or a hygiene product. In addition, the nanofibrous membrane for diagnosing urinary tract infection may have a large surface area by having a porous structure, and may easily absorb liquid or react with the liquid.

2 and 3, the sphere represents the first reagent 10, and the cube represents the second reagent 20.

Referring to FIG. 4, a cylinder including a spherical and a cube expresses the structure of the composite nanofiber 100 including the first reagent and the second reagent. The first reagent 10 and the second reagent 20 are included on the surface and inside of the composite nanofiber 100, and more specifically, carried or inclusion on the composite nanofiber. May be The supported or enclosed structure may be formed by electrospinning a solution containing a first reagent, a second reagent, and a polymer material.

Referring to FIG. 5, the composite nanofibers 100 are arranged in an irregular arrangement to show a part of the nanofibrous membrane having a porous nonwoven structure. The structure such as the nonwoven fabric may be formed by electrospinning composite nanofibers.

The first reagent is to generate a hydrolysis compound by leukocyte esterase, and the hydrolysis compound may be an aromatic compound.

The first reagent may include at least one of indole acetate or naphtol AS-D chloroacetate (3-Hydroxy-2-naphthoic-o-toluidide chloroacetate as IUPAC name). The indole acetate and the naphthol acetone chloroacetate may react with a white blood cell esterase to generate a hydrolysis compound. The indole acetate is indoxyl acetate, indoxyl butyrate, indoxyl laurate, indoxyl stearate, indoxyl esters of N-blocking amino acids or peptides, lactate esters, indole carboxylic acid esters or methyl indole-3-carboxylate. And may include at least one.

The second reagent may include a diazonium salt. The diazonium salt may generate a dye material (azole-based dye) that exhibits color by reacting with the hydrolysis compound generated by the reaction of the first reagent with the leukocyte esterase. The diazonium salt may be, for example, 1-diazo-2-naphthol-4-sulfonate; 1-diazophenyl-3-carbonate, 4-diazo-3-hydroxy-1-naphthylsulfonate (DNSA), 4-diazo-3-hydroxy-7-nitro-1-naphthyl Sulfonate (NDNSA), 4-diazo-3-hydroxy-1,7-naphthyldisulfonate, 2-methoxy-4-(N-morpholinyl)benzene diazonium chloride, 4-diazo-3 -Hydroxy-7-bromo-1-naphthylsulfonate and 4-diazo-3-hydroxy-7-[1,oxopropyl]-1-naphthylsulfonate, 5-chloro-2-methoxy Benzenediazonium chloride, or 2-chloro-4-benzamido-5-methylbenzenediazonium, and may include at least one of them.

The first reagent and the second reagent can detect leukocyte esterase present in urine. When a patient's bladder or urinary tract is infected, the number of leukocytes increases at the site of infection, so urinary tract infection can be diagnosed by detecting leukocyte esterases present in urine.

In the case of the indole carboxylic acid ester, indoxyl is generated by leukocyte esterase, and the indoxyl reacts with a diazonium salt to produce a purple azole dye. In the case of the naphthol A.S. chloroacetate, a reaction with leukocyte esterase produces a hydrolysis product, and the hydrolysis product reacts with a diazonium salt to produce a purple azole dye.

The nanofiber may include a water-soluble polymer material. The polymer material may be dissolved in a solvent to prepare an electrospinning solution, and when the electrospinning solution is electrospun, a material in the form of fibers such as short fibers or long fibers (filaments) may be manufactured. The water-soluble polymer material can have a faster chemical reaction with urine when compared to the water-insoluble polymer material. The water-soluble polymer material may be, for example, polyethylene oxide (PEO), polyethylene glycol (PEG), polyvinylpyrrolidone (PVP) and polyvinyl alcohol (PVA), preferably polyethylene Oxide.

The molecular weight (Mw) of the polymer material may be 600,000 to 1,100,000 Mw, 700,000 to 1,000,000 Mw, 800,000 to 950,000 Mw, or 800,000 to 900,000 Mw. When the molecular weight of the polymer material is higher than the above range, the viscosity of the polymer solution increases, so the diameter of the nanofibers increases and the reagent may be difficult to spread evenly. If the molecular weight of the polymer material is lower than the above range, the diameter of the nanofiber may be too small, and it may be difficult to uniformly manufacture the diameter of the nanofiber.

The composite nanofiber is 0.1 to 5%, 0.5 to 5%, 1 to 5%, 1.5 to 5%, 0.1 to 4%, 0.5 to 4%, 1 to 1, based on the total weight of the composite nanofiber. 4%, 1.5 to 4%, 0.1 to 3%, 0.5 to 3%, 1 to 3%, or 1.5 to 3% and the second reagent 0.1 to 5%, 0.5 to 5%, 1 to 5%, 1.5 To 5%, 0.1 to 4%, 0.5 to 4%, 1 to 4%, 1.5 to 4%, 0.1 to 3%, 0.5 to 3%, 1 to 3%, or 1.5 to 3%.

The ratio of the first reagent and the second reagent included in the composite nanofiber may be 2:1 to 1:2, 1.5:1 to 1:1.5, or 1.2:1 to 1:1.2 based on weight.

The nanofibers may have a diameter of 50 to 1500 nm, 150 to 1400 nm, 250 to 1300 nm, 250 to 1200 nm, or 300 to 1100 nm.

The nanofiber membrane may have a porosity of 70 to 95%, 80 to 95%, or 85 to 95%. If the porosity is too low, urine cannot be absorbed sufficiently, and the area for the reaction of the first reagent and the second reagent to diagnose urinary tract infection may not be sufficient.

The nanofibrous membrane for diagnosing urinary tract infection may further include a first layer including the first nanofiber and the second nanofiber and a diffusion barrier layer laminated on the first layer.

The diffusion barrier layer is not particularly limited in kind and lamination method as long as the first reagent can limit the diffusion of the hydrolyzed compound generated by reacting with the leukocyte esterase. The diffusion barrier may be, for example, a polymer solution containing no reagents, which is laminated by electrospinning on the nanofibrous membrane for diagnosing urinary tract infection. The anti-diffusion film can prevent the hydrolysis compound generated by the reaction of the white blood cell esterase and the first reagent from being diffused, and when applied to hygiene products such as diapers, the diffusion toward the skin side is minimized to minimize the effect on the human body. can do. For example, the water-soluble polymer is in the form of a gel when it comes into contact with urine, and the diffusion barrier can block the gel from directly contacting the skin.

In addition, the diffusion barrier layer may increase the reaction efficiency of the hydrolyzed compound and the second reagent by allowing the hydrolyzed compound to be located in close proximity to the second reagent without indiscriminate diffusion. When the efficiency of the reaction between the hydrolyzed compound and the second reagent is increased, more colored compounds are generated, so that the color may be more vivid, and it may be easy to visually observe urinary tract infection.

The apparatus for diagnosing urinary tract infection according to an embodiment of the present invention includes the nanofibrous membrane for diagnosing urinary tract infection. The apparatus for diagnosing urinary tract infection has various advantages by including the nanofibrous membrane for diagnosing urinary tract infection. First, the urinary tract infection can be visually confirmed, so it can be diagnosed without visiting a hospital. In addition, it is easy for the guardian to confirm the urinary tract infection. The apparatus for diagnosing urinary tract infection is not particularly limited as long as the nanofibrous membrane for diagnosing urinary tract infection can be applied, and may be, for example, a hygiene product such as a diagnostic sheet or a diaper. In concentrated urine, false positives may appear, and when a reducing agent such as vitamin C is present, false negatives may appear. Therefore, it is preferable to perform a test in a state in which sufficient water is consumed and a reducing agent such as vitamin C is discontinued for a certain period. .

In the method of manufacturing a nanofibrous membrane for urinary tract infection diagnosis according to an embodiment of the present invention, a first reagent for generating a hydrolyzed compound by reacting with a leukocyte esterase and a color indicating the presence of a leukocyte esterase by reacting with the hydrolyzed compound And preparing a composite polymer solution containing the second reagent shown and electrospinning the composite polymer solution into a current collector.

The composite polymer solution means a polymer solution containing both the first reagent and the second reagent.

The current collector means a place where fibers formed by discharging a positively charged polymer solution from a spinneret are gathered, and may also be referred to as a collector or a collecting plate.

The current collector may be negatively charged or grounded. The current collector is not particularly limited in shape, but may be in the form of a rotating drum.

The electrospinning may be electrospinning using a commercial mass production device, and more specifically, may be electrospinning to a device including a conveyor belt and a plurality of nozzles.

The composite polymer solution is 0.1 to 4 wt% of the first reagent, 0.1 to 4 wt% of the second reagent, 0.5 to 4 wt% of the first reagent, and 0.5 of the second reagent, based on the weight of the solute. To 4% by weight, 1.0 to 4% by weight of the first reagent, 1.0 to 4% by weight of the second reagent, 1.5 to 4% by weight of the first reagent, and 1.5 to 4% by weight of the second reagent, and 0.1 to 3% by weight of the first reagent, 0.1 to 3% by weight of the second reagent, 0.5 to 3% by weight of the first reagent, 0.5 to 3% by weight of the second reagent, and 1.0 to 3% of the first reagent 3% by weight and 1.0 to 3% by weight of the second reagent, 1.5 to 3% by weight of the first reagent, 1.5 to 3% by weight of the second reagent, 0.1 to 2% by weight of the first reagent and the agent 2 0.1 to 2% by weight of the reagent, 0.5 to 2% by weight of the first reagent, 0.5 to 2% by weight of the second reagent, 1.0 to 2% by weight of the first reagent, and 1.0 to 2% of the second reagent Weight percent, or 1.5 to 2 weight percent of the first reagent and 1.5 to 2 weight percent of the second reagent.

The solute means the remainder excluding the solvent in the composite polymer solution, and may mean, for example, a first reagent, a second reagent, and a polymer material.

The first reagent may include at least one of indole acetate or Naphtol AS-D chloroacetate. The first reagent and indole acetate are the same as described above.

The second reagent may include a diazonium salt. The second reagent and diazonium salt are the same as described above.

The polymer material may be water-soluble. The water-soluble polymer material is the same as described above.

In the electrospinning step, the electrospinning conditions include flow rates of 0.5 to 1.5 ml/h, 0.6 to 1.5 ml/h, 0.7 to 1.5 ml/h, 0.8 to 1.5 ml/h, 0.9 to 1.5 ml/h, 1.0 to 1.5 ml/h, 0.5 to 1.4 ml/h, 0.6 to 1.4 ml/h, 0.7 to 1.4 ml/h, 0.8 to 1.4 ml/h, 0.9 to 1.4 ml/h, 1.0 to 1.4 ml/h, 1.1 to 1.4 ml /h, 1.2 to 1.4ml/h, 1.3 to 1.4ml/h, 0.5 to 1.3ml/h, 0.6 to 1.3ml/h, 0.7 to 1.3ml/h, 0.8 to 1.3ml/h, 0.9 to 1.3ml/ h, 1.0 to 1.3 ml/h, 1.1 to 1.3 ml/h, 1.2 to 1.3 ml/h, 0.5 to 1.2 ml/h, 0.6 to 1.2 ml/h, 0.7 to 1.2 ml/h, 0.8 to 1.2 ml/h , 0.9 to 1.2 ml/h, 1.0 to 1.2 ml/h, 1.1 to 1.2 ml/h, 0.5 to 1.1 ml/h, 0.6 to 1.1 ml/h, 0.7 to 1.1 ml/h, 0.8 to 1.1 ml/h, 0.9 to 1.1 ml/h, 1.0 to 1.1 ml/h, 0.5 to 1.0 ml/h, 0.6 to 1.0 ml/h, 0.7 to 1.0 ml/h, 0.8 to 1.0 ml/h, or 0.9 to 1.0 ml/h days Can be. If the flow rate of the solution is too low, the electrostatic density increases and the viscosity of the spinning solution becomes relatively lower than the surface tension, so the diameter of the fiber may decrease. If the flow rate of the solution is too high, the electrostatic density may decrease and the diameter of the fiber may increase.

In the electrospinning step, the voltage for the electrospinning is 5 to 20 KV, 8 to 20 KV, 10 to 20 KV, 5 to 15 KV, 8 to 15 KV, 10 to 15 KV, 5 to 12 KV, 8 to 12 KV, or 10 to 12 KV. Can be If the voltage is too high, radiation may proceed too quickly, which may cause the solvent to not volatilize. If the voltage is too low, the radiation may not proceed smoothly.

In the electrospinning step, the electrospinning conditions include a radiation distance of 8.0 to 12.0 cm, 9.0 to 12.0 cm, 10.0 to 12.0 cm, 11.0 to 12.0 cm, 8.0 to 11.0 cm, 9.0 to 11.0 cm, 10.0 to 11.0 cm, 8.0 to 10.0 cm, or 9.0 to 10.0 cm.

Radiation distance refers to the distance between a spinneret (which may also be referred to as a nozzle or tip) and a collector.

When the TIP to Collector Distance (TCD) is too short, the solvent may reach the current collector in a state in which no volatilization occurs, resulting in a problem that fibers are larger than a desired diameter or beads are formed. If the radiation distance is too long, the electric field is weak and radiation cannot be properly performed.

Hereinafter will be described in more detail through an embodiment of the present invention. However, these examples are for illustrative purposes only, and the present invention is not limited to the following examples.

<Example: Preparation of fibrous membrane for urinary tract infection diagnosis with composite polymer solution>

1. Preparation of a composite polymer solution

The composition ratio of the composite polymer solution is 9% by weight of solute and 91% by weight of water as the solvent based on the total weight of the solution.

The solute is 97.6% by weight of PEO by weight, 1.2% by weight of the first reagent Naphthol AS-D Chloroacetate and 2-chloro-4-benzomido-5-methylbenzenediazonium as the second reagent 1.2% by weight.

According to the composition ratio of the composite polymer solution, it was mixed with naphthol acetone chloroacetate, 2-chloro-4-benzomido-5-methylbenzenediazonium and water.

First, water and PEO (Polyethylene Oxide) were stirred with a magnetic stirrer for about 12 hours, the first reagent and the second reagent were added, and the mixture was further stirred for 3 hours to prepare a composite polymer solution.

2. Electric radiation

The composite polymer solution was loaded on a syringe.

The composite polymer solution loaded on the syringe was electrospun.

The conditions for electrospinning are 1 ml/h flow rate, voltage 10 KV, and tip to collector distance (TCD) 10 cm. The spinneret uses a G18 needle and has a diameter of 1 mm.

As a result of the electrospinning, the solvent evaporated smoothly during the electrospinning. A dried fiber membrane containing composite nanofibers remained in the current collector.

<Experimental Example 1: Confirming the composition ratio>

The composition ratio of the fibrous membrane for diagnosing urinary tract infection of the Example in which all the solvent was evaporated was measured.

The composite nanofibers are 1.2% by weight of naphthol eds chloroacetate, 1.2% by weight of 2-chloro-4-benzomido-5-methylbenzenediazonium and 97.6% by weight of PEO based on the total weight of the fiber membrane.

<Experimental Example 2: Fiber membrane structure for urinary tract infection diagnosis>

The structure of the nanofibrous membrane for diagnosing urinary tract infection prepared in Example was measured by SEM. Measurement conditions are WD 15.9mm, 15.0kv, x10K.

Referring to FIG. 1, the composite nanofiber has a porous structure entangled, and the porosity is about 90%. The diameter of the composite nanofiber is about 300 to 1000 nm, and on average it is 500 nm.

10: first reagent
20: second reagent
100: composite nanofiber

Claims (14)

As a nanofibrous membrane for diagnosing urinary tract infection comprising irregularly arranged nanofibers,
The nanofibers include a first nanofiber comprising Naphthol AS-D Chloroacetate as a first reagent and 2-chloro-4-benzomido-5-methylbenzenediazonium as a second reagent. A composite nanofiber comprising a second nanofiber,
The nanofiber comprises a water-soluble polymer material,
The nanofiber membrane comprises 1.2% by weight of the first reagent and 1.2% by weight of the second reagent based on the total weight of the nanofibers,
The diameter of the nanofiber is 300 to 1000, the porosity of the nanofiber membrane is 80 to 95%,
The first reagent generates a hydrolysis compound by leukocyte esterase,
The second reagent reacts with the hydrolyzed compound to exhibit a color indicating the presence of leukocyte esterase,
Nanofibrous membrane for urinary tract infection diagnosis.
delete delete delete delete delete delete According to claim 1,
A first layer comprising the first nanofiber and the second nanofiber; And
Further comprising a diffusion barrier layer laminated on the first layer
Nanofibrous membrane for urinary tract infection diagnosis.
A device for diagnosing urinary tract infection comprising the nanofibrous membrane for diagnosing urinary tract infection according to claim 1.
As a method of manufacturing a nano-fiber membrane for diagnosing Oro infection according to claim 1,
As a first reagent that reacts with leukocyte esterase to produce a hydrolyzed compound, Naphthol AS-D Chloroacetate and reacts with the hydrolyzed compound to display a color indicating the presence of leukocyte esterase. 2 preparing a composite polymer solution containing 2-chloro-4-benzomido-5-methylbenzenediazonium as a reagent, and
Comprising the step of electrospinning the composite polymer solution,
The composite polymer solution contains 1.2% by weight of the first reagent and 1.2% by weight of the second reagent as a solute, and the diameter of the nanofiber is 300 to 1000, and the porosity of the nanofiber membrane is 80 to 95%. Method for manufacturing nanofibrous membrane for diagnosing phosphorus and urinary tract infection.
delete delete delete The method of claim 10,
The polymer material is water-soluble,
Method for manufacturing nanofibrous membrane for urinary tract infection diagnosis.

Images